Dermata Therapeutics Inc
DRMA
Detailliertes Diagramm anzeigen
3.070USD
-0.350-10.23%
Handelsschluss 11/04, 16:00（ET）Kurse um 15 Minuten verzögert
195.79KMarktkapitalisierung
VerlustKGV TTM
Intraday
1m
30m
1h
D
W
M
D
Heute
-10.23%
5 Tage
-18.35%
1 Monat
-36.83%
6 Monate
+252.91%
Seit Jahresbeginn
+127.41%
1 Jahr
+152.03%
Detailliertes Diagramm anzeigen
TradingKey Aktienbewertung von Dermata Therapeutics Inc
Währung: USD Aktualisiert: 2025-10-27Wichtige Einblicke
Seine Bewertung wird als unterbewertet angesehen,und die institutionelle Anerkennung ist sehr hoch. In den letzten 30 Tagen haben mehrere Analysten die Aktie mit einer Kaufen bewertet. Der Aktienkurs bewegt sich seitwärts zwischen den Unterstützungs- und Widerstandsniveaus, was ihn für schwankungsorientiertes Trading geeignet macht.
Dermata Therapeutics Inc Bewertung
Widerstand & Unterstützung
Keine Daten
Radar Chart
Aktueller Preis
Vorher
Analysten-Ziel
Basierend auf insgesamt
1
Analysten
Kaufen
Aktuelles Rating
10.000
Kursziel
+192.40%
Aufwärtspotenzial
Hinweis: Analystenbewertungen und Kursziele werden von LSEG ausschließlich zu Informationszwecken bereitgestellt und stellen keine Anlageberatung dar.
Dermata Therapeutics Inc Highlights
HöhepunkteRisiko
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, DMT310, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 50 million patients. Its second product candidate utilizing its Spongilla technology is DMT410, its combination treatment. DMT410 is intended to consist of one treatment of its proprietary sponge powder followed by one topical application of botulinum toxin for delivery into the dermis.
high_profit_growth
high_profit_growth_desc%!(EXTRA string=0.00)
valuation_overestimated
valuation_overestimated_desc%!(EXTRA string=PE, string=-0.08)
institutional_decreasing_position
institutional_decreasing_position_desc%!(EXTRA string=50.82K, string=2.63%)
Dermata Therapeutics Inc Nachrichten
Bald gibt es mehr Neuigkeiten, bleiben Sie dran...
Finanzindikatoren
EPS
Keine Daten
Gesamteinnahmen
Keine Daten
Dermata Therapeutics Inc Informationen
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, DMT310, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 50 million patients. Its second product candidate utilizing its Spongilla technology is DMT410, its combination treatment. DMT410 is intended to consist of one treatment of its proprietary sponge powder followed by one topical application of botulinum toxin for delivery into the dermis.
BörsenkürzelDRMA
UnternehmenDermata Therapeutics Inc
CEOMr. Gerald T. (Gerry) Proehl
Websitehttps://www.dermatarx.com/
Verwandte Finanzinstrumente
+1.15%
+0.32%
+1.85%
+0.38%
+0.93%
+1.66%
-1.75%
+0.13%
+0.78%
-1.46%
-1.88%
-1.02%
+2.61%
+1.01%
-0.93%
-0.64%
0.00%
-2.22%
-2.44%
-13.78%Beliebte Symbole
